Ajanta Pharma Philippines Inc Pharmaceutical Import Profile — Philippines (DGFT 2022–2026)

Name: Ajanta Pharma Philippines Inc Pharmaceutical Import Records from India — 7 Products, $5.3M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Ajanta Pharma Philippines Inc — Pharmaceutical Importer Profile (2026) | 7 Products, $5.3M Trade | TransData Nexus

Ajanta Pharma Philippines Inc

Pharmaceutical Importer · Philippines · Lipid & Metabolism Focus · $5.3M Total Trade · DGFT Verified

Ajanta Pharma Philippines Inc is a pharmaceutical importer based in Philippines with a total trade value of $5.3M across 7 products in 5 therapeutic categories. Based on 109 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Ajanta Pharma Philippines Inc sources from 1 verified Indian supplier, with Ajanta Pharma Limited accounting for 100.0% of imports.

Ajanta Pharma Philippines Inc — Import Portfolio & Supplier Network

Ajanta Pharma Philippines Inc import network — 7 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Ajanta Pharma Philippines Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Ajanta Pharma Limited	$18.5M	581	100.0%

Ajanta Pharma Philippines Inc sources from 1 verified Indian supplier across 371 distinct formulations. The sourcing is highly concentrated — Ajanta Pharma Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Ajanta Pharma Philippines Inc Import?

Formulation	Value	Ships
Rosucol TAB 10MG[39330packx3x10=1179900tabs]Each film coated TAB cont:rosuvastatin calcium eq. to rosuvastatin	$176.3K	4
Tamplus 400 [26090 packx3x10=782700 CAPS] tamsulosin hydrochloride (as sustainedrelease pellets)as per	$150.0K	3
Tamplus 200 [26137 packx3x10=784110 CAPS] tamsulosin hydrochloride (as sustainedrelease pellets)as per	$150.0K	3
Tamplus 400[26145packx3x10=784350 CAPS]tamsulosin hydrochloride(as sustained release pellets)plus finasteride as per	$150.0K	3
Tamplus 400[26145packx3x10=784350caps]tamsulosin hydrochloride(as sustained release pellets) plus finasteride as per	$150.0K	3
Atenurix 40[105297packx3x10=3158910 tabs]Each film coated TAB cont:febuxostat	$150.0K	3
Tamplus 400[26217packx3x10=786510caps]tamsulosin hydrochloride (as sustained release pellets plus finasteride as per	$150.0K	3
Glipten TAB 20 MG [38970packx3x10=1169100tabs]Each film coated TAB cont:teneligliptin hydrobromide hydrate eq as per	$150.0K	3
Tamplus 200[26145packx3x10=784350caps]tamsulosin hydrochloride (as sustained release as per inv [Each capsule contains	$150.0K	3
Atenurix TAB 20MG [52176 x 3 x 10 = 1565280 tablets] [Each film coated tablet contains : febuxostat 20	$148.4K	3
Rosufen 10/160[25960packx3x10=778800 tabs](rosuvastatin 10MG + fenofibrate 160mgtabs	$147.0K	3
Razine TAB 500 MG[9670packx3x10=290100	$139.7K	3
Alzor ccb TAB 20/5MG [25245 packx3x10=757350 tabs][olmesartan medoxomil and amlodipine tablets] as per	$135.1K	3
Alzor ccb TAB 20/5MG[25412x3x10=762360][olmesartan medoxomil and amlodipine tablets][Each film coatd tablet	$133.4K	3
Alzor tabs 20 MG[26105packx3x10=783150tab]olmesartan medoxomil tabs 20MG]Each film coated TAB cont:olmesartan as per	$126.3K	3

Import Portfolio — Top 7 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Febuxostat	Lipid & Metabolism	$1.3M	25	2.6%	2
2	Cetirizine	Antihistamines & Allergy	$1.0M	20	0.6%	8
3	Pioglitazone	Diabetes & Endocrine	$800.0K	16	2.1%	8
4	Montelukast	Respiratory	$750.0K	15	0.4%	11
5	Glimepiride	Diabetes & Endocrine	$600.0K	12	0.8%	5
6	Fenofibrate	Lipid & Metabolism	$500.0K	10	0.7%	10
7	Warfarin	Cardiovascular	$374.2K	11	5.1%	5

Ajanta Pharma Philippines Inc imports 7 pharmaceutical products across 5 categories into Philippines totaling $5.3M.

Ajanta Pharma Philippines Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Ajanta Pharma Philippines Inc. (AAPI) is a wholly owned subsidiary of Ajanta Pharma Limited, a specialty pharmaceutical company headquartered in Mumbai, India. Established on April 11, 2008, AAPI is based in Metro Manila, Philippines. The company specializes in the development, manufacture, and marketing of premium pharmaceutical products, focusing on introducing first-to-market compounds, unique therapeutically optimized combinations, and value-branded equivalents. (ajantapharma.com.ph)

AAPI has rapidly positioned itself among the top 35 pharmaceutical corporations distributing prescription-only medicines in the Philippines. This achievement is attributed to its strategic approach of introducing innovative pharmaceutical compounds and fixed-dose combinations that address specific therapeutic needs. The company's product portfolio spans various therapeutic areas, including lipid and metabolism disorders, diabetes and endocrine conditions, and antihistamines and allergy treatments. (ajantapharma.com.ph)

2Distribution Network

Ajanta Pharma Philippines Inc. operates from its headquarters located at 1702 AXA Life Center, 1286 Sen. Gil Puyat Avenue, Makati City, Metro Manila, Philippines. (ph42458-ajanta-pharma-philippines-inc.contact.page) While specific details regarding warehouse locations and logistics capabilities are not publicly disclosed, the company's strategic positioning in Metro Manila suggests a centralized distribution model. This centralization likely facilitates efficient logistics and broad geographic coverage within the Philippines. Given the absence of information on operations beyond the Philippines, it is reasonable to infer that AAPI's distribution network primarily serves the domestic market.

3Industry Role

Ajanta Pharma Philippines Inc. functions as a pharmaceutical importer and distributor within the Philippine market. By sourcing finished pharmaceutical formulations from its parent company, Ajanta Pharma Limited, and other suppliers, AAPI plays a pivotal role in introducing innovative and specialized pharmaceutical products to the local market. Its focus on first-to-market compounds and unique fixed-dose combinations positions AAPI as a key player in addressing specific therapeutic needs in the Philippines. (ajantapharma.com.ph)

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Ajanta Pharma Philippines Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Ajanta Pharma Philippines Inc. demonstrates a high degree of sourcing concentration, with 100% of its pharmaceutical imports originating from Ajanta Pharma Limited. This exclusive sourcing strategy indicates a strategic partnership aimed at ensuring product consistency, quality control, and supply chain reliability. The substantial volume of imports—totaling $5.3 million USD across 109 shipments—reflects a stable and ongoing relationship between AAPI and its parent company. However, this single-source dependency also exposes AAPI to potential risks associated with supply chain disruptions, such as manufacturing delays or regulatory challenges faced by the supplier.

The concentration of imports in a limited number of products—seven across five therapeutic categories—suggests a focused product strategy. The top five products alone account for 83.4% of the total import value, highlighting a reliance on a narrow product range. While this focus allows for specialization and expertise in specific therapeutic areas, it also means that any issues affecting these key products could significantly impact AAPI's operations and market presence.

2Supply Chain Resilience

The resilience of Ajanta Pharma Philippines Inc.'s supply chain is closely tied to its exclusive sourcing arrangement with Ajanta Pharma Limited. This direct relationship likely ensures stringent quality control and adherence to regulatory standards, given the shared corporate governance and operational protocols. However, the lack of publicly available information regarding backup suppliers or alternative sourcing strategies indicates a potential vulnerability. In the event of disruptions at Ajanta Pharma Limited's manufacturing facilities or challenges in the Indian supply chain, AAPI may face difficulties in maintaining a consistent product supply. The absence of diverse formulations in the import portfolio further underscores this risk, as the company is heavily dependent on a limited range of products.

Importing Pharmaceuticals into Philippines — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Philippines

1Regulatory Authority & Framework

In the Philippines, the Food and Drug Administration (FDA) is the primary regulatory body overseeing the importation, registration, and distribution of pharmaceutical products. The FDA ensures that all pharmaceutical imports comply with the country's health and safety standards. Key legislation governing pharmaceutical imports includes the Food, Drug, and Cosmetic Act, which outlines the requirements for drug registration, labeling, and quality control. The marketing authorization pathway for Indian generics involves obtaining FDA approval, which requires submission of comprehensive documentation, including clinical trial data, manufacturing processes, and quality control measures. This rigorous process ensures that imported generics meet the therapeutic equivalence and safety standards established by the FDA.

2Import Licensing & GMP

Import licensing requirements in the Philippines mandate that pharmaceutical importers possess a valid License to Operate (LTO) and Drug Distributor-Importer authorization from the FDA. These licenses confirm that the importer complies with the FDA's standards for drug distribution and importation. Good Manufacturing Practice (GMP) certification is also a critical component of the import process. The FDA recognizes GMP certifications from reputable international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and the Pharmaceutical Inspection Co-operation Scheme (PIC/S). Pharmaceutical products imported into the Philippines must be manufactured in facilities holding these certifications to ensure product quality and safety. Additionally, importers must obtain wholesale distribution authorization, which involves demonstrating the capability to store, handle, and distribute pharmaceutical products in compliance with FDA regulations.

Ajanta Pharma Philippines Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Ajanta Pharma Philippines Inc.'s product strategy focuses on introducing first-to-market pharmaceutical compounds, unique therapeutically optimized combinations, and value-branded equivalents. This approach addresses specific therapeutic needs in the Philippine market, particularly in areas such as lipid and metabolism disorders, diabetes and endocrine conditions, and antihistamines and allergy treatments. The market demand for these products is driven by the increasing prevalence of chronic diseases, a growing aging population, and a heightened awareness of health and wellness among consumers. By focusing on these therapeutic areas, AAPI aims to provide innovative solutions that improve patient outcomes and meet the evolving healthcare needs of the Filipino population.

2Sourcing Profile

Ajanta Pharma Philippines Inc. primarily sources its pharmaceutical products from its parent company, Ajanta Pharma Limited, in India. This sourcing strategy emphasizes the procurement of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, rather than raw active pharmaceutical ingredients (APIs) or bulk drugs. The focus on finished formulations allows AAPI to ensure product quality and consistency, leveraging the manufacturing capabilities and regulatory compliance of its parent company. India's robust pharmaceutical manufacturing sector, with its adherence to international GMP standards, aligns with AAPI's commitment to delivering high-quality pharmaceutical products to the Philippine market.

Frequently Asked Questions — Ajanta Pharma Philippines Inc

What products does Ajanta Pharma Philippines Inc import from India?

Ajanta Pharma Philippines Inc imports 7 pharmaceutical products across 5 categories. Top imports: Febuxostat ($1.3M), Cetirizine ($1.0M), Pioglitazone ($800.0K), Montelukast ($750.0K), Glimepiride ($600.0K).

Who supplies pharmaceuticals to Ajanta Pharma Philippines Inc from India?

Ajanta Pharma Philippines Inc sources from 1 verified Indian suppliers. The primary supplier is Ajanta Pharma Limited (100.0% of imports, $18.5M).

What is Ajanta Pharma Philippines Inc's total pharmaceutical import value?

Ajanta Pharma Philippines Inc's total pharmaceutical import value from India is $5.3M, based on 109 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Ajanta Pharma Philippines Inc focus on?

Ajanta Pharma Philippines Inc imports across 5 categories. The largest: Lipid & Metabolism (33.2%), Diabetes & Endocrine (26.5%), Antihistamines & Allergy (19.0%).

Get Full Ajanta Pharma Philippines Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. For current shipment-level data, contact TransData Nexus.

Ajanta Pharma Philippines Inc

Ajanta Pharma Philippines Inc — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Ajanta Pharma Philippines Inc?

What Formulations Does Ajanta Pharma Philippines Inc Import?

What Products Does Ajanta Pharma Philippines Inc Import?

Top Products by Import Value

Ajanta Pharma Philippines Inc Therapeutic Categories — 5 Specializations